[The protective effects of Zn-metallothionein on severely scalded rats inflicted by oxygen free radicals].
OBJECTIVE
To investigate the protective effects of metallothionein (MT) on severely scalded rats inflicted by oxygen free radicals after delayed resuscitation.


METHODS
Wistar rats inflicted by 30% TBSA III degree scalding injury were taken as the model. Fifty-Six rats were randomly divided into four groups, i.e. normal control, delayed resuscitation, MT treated and VitC treated groups. The changes in superoxide dismutase (SOD) and malondialdehyde (MDA) contents in plasma and subeschar edematous fluid were determined at 24 and 48 postburn hours with traditional indirect detecting method and electron spin resonance (ESR). Pathomorphological examination was simultaneously carried out for cardiac, hepatic, renal and intestinal samples. Plasma biochemical indices were determined at the same time.


RESULTS
In delayed resuscitation group, SOD content decreased and the MDA contents increased in plasma and subeschar fluid obviously, with remarkable changes in the pathomorphology of all the internal organs and the blood biochemical indices. But in MT treating group, SOD content increased (P < 0.05) with decreased content of MDA (P < 0.05) and the pathomorphology and blood biochemical indices improved significantly when compared with those in delayed resuscitation group and VitC treatment group.


CONCLUSIONS
MT treatment might be beneficial in the management of severely scalding rats infliced by oxygen free radicals.
Chen
X
X
Department of Burns, Beijing Ji Shui Tan Hospital, Beijing 100035, P.R. China.
Qin
F
F
Cheng
S
S
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology; D001219:Aspartate Aminotransferases / Q000097:blood; D001806:Blood Urea Nitrogen; D001826:Body Fluids / Q000378:metabolism; D002056:Burns / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003402:Creatine Kinase / Q000097:blood / Q000187:drug effects; D052279:Creatine Kinase, MB Form; D005260:Female; D006884:Hydroxybutyrate Dehydrogenase / Q000097:blood / Q000187:drug effects; D007527:Isoenzymes / Q000097:blood / Q000187:drug effects; D007770:L-Lactate Dehydrogenase / Q000097:blood / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008668:Metallothionein / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism*; D013482:Superoxide Dismutase / Q000097:blood / Q000187:drug effects; D013997:Time Factors
D007527:Isoenzymes; D017382:Reactive Oxygen Species; D008315:Malondialdehyde; D008668:Metallothionein; D007770:L-Lactate Dehydrogenase; D006884:Hydroxybutyrate Dehydrogenase; D013482:Superoxide Dismutase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D001205:Ascorbic Acid